<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782080</url>
  </required_header>
  <id_info>
    <org_study_id>Stei-Sed-0106</org_study_id>
    <nct_id>NCT00782080</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD</brief_title>
  <official_title>Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Huss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Steiner Arzneimittel, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and efficacy of an herbal treatment in children and
      adolescents with ADHD.

      Study Design:

        -  Randomized

        -  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

        -  Placebo Control

        -  Parallel Assignment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADHD is a common childhood disorder associated with attention problems and disruptive
      behavior. Clinical evidence suggests that a herbal drug combination of St. John´s Wort
      /Valerian extract may be effective in treating ADHD symptoms in methylphenidate and
      atomoxetine naive patients. This study will determine the safety and efficacy of an herbal
      treatment in children and adolescents with ADHD.

      Participants will be randomly assigned to receive either an herbal product or placebo twice a
      day for the duration of 8 weeks. Participants will come in for study visits after 2 and 8
      weeks for the assessment of ADHD symptoms, performance and spontaneous movements. Side
      effects will be monitored continuously and also assessed by rating scales.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD-IV rating scale</measure>
    <time_frame>Difference in total score between baseline and end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barkley´s Side Effects Rating Scale</measure>
    <time_frame>Difference between baseline and each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Sedariston</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo campsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo provided by the company given orally in capsules (size 1 )twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sedariston</intervention_name>
    <description>St. John´s Wort (100 mg) Valerian Extract (50 mg)</description>
    <arm_group_label>Sedariston</arm_group_label>
    <other_name>Sedariston Concentrate(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo campsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV Diagnosis of ADHD

          -  Score of ADHDRS-IV-Parent Version ≥24

          -  Sufficient knowledge of the German language

          -  Written Informed Consent by parents and patients

          -  Ability to swallow study medication

          -  Sexually mature and active adolescents with highly effective methods of birth control:

               -  contraception according to Pearl-Index &lt; 1

               -  when use of oral contraceptives, additional methods of contraception (e.g.
                  condoms) are necessary, i.e. double-barrier

        Exclusion Criteria:

          -  Known hypersensitivity against St. John´s wort or Valerian root or one of the
             excipients

          -  Known hypersensitivity of the skin when exposed to sunlight

          -  All serious internal diseases, and for this reason: Current intake of the following
             medication:

               -  Ciclosporin, Tacrolimus, Indinavir and other protease inhibitors in the anti-HIV
                  treatment

               -  Irinotecan and other cytostatics

               -  anticoagulants of the Cumarin-type, Digoxin, Amitriptylin, Nortriptyline

               -  Midazolam, Theophylline or other medication with photosensitive effects

          -  All severe psychiatric diseases except oppositional defiant disorders (according to
             items 21-28 SNAP-IV) and conduct disorders (according to items 41-45 SNAP-IV), and for
             this reason current intake of the following medication: antidepressants and other
             psychotropic medication

          -  Indication for hospitalization

          -  Suicidality (including suicidal thoughts): Score ≥3 in item 10 of MADRS

          -  Pregnancy, lactation

          -  IQ &lt; 70

          -  Positive screening for metabolites of illegal drugs in urine

          -  Previous medication with stimulants and/or atomoxetine

          -  Psychotropic co-medication

          -  Placement in an institution on official or judicial ruling

          -  Parallel participation in another clinical trial according to German Drug Law (AMG),
             or less than 4 weeks ago

          -  Patients requiring a primary medication with methylphenidate during the study period
             of 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Huss, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University, Mainz, Dep. of Child and Adolescent Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheinhessenfachklinik</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Fachklinik für Kinder- und Jugendpsychiatrie</name>
      <address>
        <city>Bad Neuenahr</city>
        <zip>53474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Kinder- und Jugendpsychiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité University</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Prof. Huss</investigator_full_name>
    <investigator_title>Prof. Dr. med. Dipl.-Psych. Michael Huss</investigator_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>St. John`s Wort</keyword>
  <keyword>Valerian extract</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

